Interventional Radiology

More information is available in Swedish.
 

Members of the group 2016:

Rickard Nyman, Ass Professor
Pär Gerwins, Ass Professor
Charlotte Ebeling Barbier, MD
Lars-Gunnar Eriksson, MD
Hampus Eklöf, MD
Kerstin Rosenqvist, PhD Student
 

In collaboration with:

Dan Granberg, MD, Endokrinonkologen
Per Sangfelt och Fredrik Rorsman Gastroenterologen
Hans Lennernäs, professor, Elsa Lilienberg, MD, Ilse Dubbelboer, doktorand, Farmakologiska institutionen.
Per Stål, adjungerad professor, Gastoenterologen, Omar Karalli, Dr, röntgen, Huddinge sjukhus.
Teus van der Laar, Dr, UMCG, Groningen. Dag Nyholm, MD, Neurologen.
Magnus Sundbom, MD, och Mikael Ljungdahl, Eladio Cabrera, doktorand, kirurgen
Bengt Fellström, professor, Hans Furuland, MD, njurmedicin


Project 1: Radioembolisering av levertumörer – effekt och lärdomar

Information about this project is only available in Swedish (see the Swedish version).

Members of the group 2016:

Charlotte Ebeling Barbier, MD
Rickard Nyman, Adjungerande Profesor
Ulrike Garske, MD
Dan Granberg, MD
 

Project 2: Behandling med transjugulär intrahepatisk portosystemisk shunt (TIPSS) hos patienter med portal hypertension.

Information about this project is only available in Swedish (see the Swedish version).

Members of the group 2016:

Rickard Nyman, adjungerand professor
Fredrik Rorsman, MD
Per Sangfelt, MD
Charlotte Ebeling-Barbier, MD
Lars-Gunnar Eriksson, MD
Kerstin Rosenqvist, doktorand
Reza Sheikhi, doktorand
 

Project 3: En öppen, parallell, singeldos multicenterstudie för utvärdering av doxorubicins och doxorubicinols farmakokinetik efter intraarteriell injektion med DC Beads eller emulsion

Information about this project is only available in Swedish (see the Swedish version).

Members of the group 2016:

Hans Lennernäs, Professor
Elsa Lilienberg, MD
Ilse Dubbelboer, doktorand, Farmakologiska institutionen
Per Stål, adjungerand professor, Gastoenterologen
Omar Karalli, Dr, röntgen, Huddinge sjukhus
Charlotte Ebeling-Barbier, MD
 

Project 4: Post Market Clinical Follow-Up study on the T-Port® Enteral Access System

Multicenter, non-randomized, open labelled, observational study where Parkinson patients who have been prescribed the T-Port as the access system for delivery of Duodopa to the jejunum will be monitored carefully and systemically the first year following the implantation.

Members of the group 2016:

Teus van der Laar, Dr, UMCG, Groningen
Dag Nyholm, MD, Neurologen.
Rickard Nyman, adjungerand professor
 

Project 5: Perkutan Endoscopisk Gastrostomi (PEG) kontra Radiologiskt Insatt Gastrostomi (RIG): en prospektiv, randomiserad studie.

Information about this project is only available in Swedish (see the Swedish version).

Members of the group 2016:

Magnus Sundbom, MD
Mikael Ljungdahl, MD
Eladio Cabrera, doktorand, kirurgen
Rickard Nyman, adjungerand professor

Project 6: Pilot Study on the Use of a Novel Hemodynamic Access System for patient on Haemodialysis. The HAS-01 Study

The hemodynamic access port (HAS-port) for hemodialysis has been developed to address some of these problems. The development of the product builds upon the experience from the clinical use of the CE-marked product T-Port© Enteral Access System (T-Port), which was developed for catheter access to the stomach and small intestine. The T-port has mainly been used for continuous infusion of L-Dopa to the small intestine in patients with severe symptoms of Parkinson’s disease. The port has a perforated plate that lies subcutaneous allowing the tissue to grow into it and stabilizing the port with creation of a tissue seal against bacterial invasion. The HAS-port will replace the catheter penetration of the skin and thereby possibly reducing the risk for bacteria invasion around the catheter.  With the special designed mechanism to open and close the port before and after dialysis the risk of bacterial contamination during handling of the connection is believed to be reduced. Therefore, it is believed that the port can facilitate the dialysis and reduce the risk for serious infection. If functional problems occurs with the catheter the port can be easily opened in an aseptic way allowing for investigation of the cause with exchanged of catheter and/or performing procedures such as thrombolysis, balloon dilation or stripping of fibrous sheath. As the opening of the port means no interference with the skin the risk for bacteria contamination is believed to be reduced.

The hypothesis is that the port will heal in uneventfully during the first month and that the central venous catheter (CVC) will maintain acceptable blood flow (> 300 ml/min) on the dialysis machine during 6 months. The number of complications (inflectional or functional) that results in hospitalization or intervention during 6 months due to the use of HAS-port for hemodialysis will be analyzed and compared with historical data of conventional CVC catheters. Incidence for bacteremia is at an average to be between 2-6/1000 catheter days, which means that the number of bacteremia with 10 HAS-port during 6 months should not be more than 10 and most likely stay less than 5 episodes.

Members of the group 2016:

Bengt Fellström, professor, njurmedicin
Hans Furuland, MD, njurmedicin
Rickard Nyman, adjungerad professor
Johan Ryden, Transcutan AB